scispace - formally typeset
P

Pamela M. Ward

Researcher at Roswell Park Cancer Institute

Publications -  20
Citations -  586

Pamela M. Ward is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Metastasis & Gene rearrangement. The author has an hindex of 12, co-authored 20 publications receiving 576 citations.

Papers
More filters
Journal ArticleDOI

Cell detachment and metastasis.

TL;DR: The arrest of cancer cells at the vascular endothelium and their subsequent release have been associated with the presence of platelets, and the deposition of fibrin and manipulation of platelet-aggregating mechanisms and fibrinolysis are discussed in terms of their antimetastatic effects.
Journal ArticleDOI

Neutropenia Associated With T-Cell Large Granular Lymphocyte Leukemia: Long-Term Response to Cyclosporine Therapy Despite Persistence of Abnormal Cells

TL;DR: It is concluded that CSA is an effective therapy for neutropenia associated with T-LGL leukemia, and that resolution of neutropania despite persistence of abnormal cells implies thatCSA may inhibit T- LGL secretion of yet unidentified mediators of neutopenia.
Journal ArticleDOI

Clonal evolution in B-lineage acute lymphoblastic leukemia by contemporaneous VH-VH gene replacements and VH-DJH gene rearrangements

TL;DR: Oligoclonal rearrangements evolved by two independent, yet seemingly contemporaneous molecular genetic mechanisms that may have relevance to the recombinatorial opportunities available during normal B-cell maturation.
Journal ArticleDOI

Liver-to-lung traffic of cancer cells.

TL;DR: It is suggested that the death of most circulating cancer cells passing through the first organ encountered after leaving their primary tumor, serves to severely limit their further direct spread to other organs.
Journal Article

Endogenous CD8+ T Cell Expansion During Regression of Monoclonal EBV-Associated Posttransplant Lymphoproliferative Disorder

TL;DR: The striking temporal relationship between the endogenous expansion of a TCR Vbeta-restricted, CD3+CD8+ population of MHC class I-restricted CTL, and the regression of an autologous monoclonal PTLD, provides direct evidence in humans that endogenous CD3 + CD8+ CTLs can be responsible for effective immune surveillance against malignant transformation of EBV+ B cells.